Progyny has delivered four consecutive earnings beats averaging 15.5% above estimates with excellent free cash flow conversion of 296%, but the stock has reached analyst targets and the current price offers no meaningful upside cushion.
Thesis pillars
- Quality Cashflow Strength→Stable
- Earnings Beat Consistency→Stable
- Valuation Target Exhaustion↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Progyny, Inc. (PGNY) Stock Analysis
Inst Constrain edge
Healthcare · Healthcare Plans
Hold if already holding. Not a fresh buy at $25.44, but acceptable to hold if already in. Reason: Negative momentum.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle;... Read more
Hold if already holding. Not a fresh buy at $25.44, but acceptable to hold if already in. Reason: Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 40d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-09-26Recent Developments — Progyny, Inc.
Latest news
- NEWS Progyny Inc (PGNY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey — TradingKey neutral
- NEWS Progyny Inc (PGNY) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com — tradingkey.com neutral
- NEWS Progyny Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs — Revelio Labs neutral
- NEWS Should Value Investors Buy Progyny (PGNY) Stock? - Yahoo Finance — Yahoo Finance positive
- NEWS Progyny Buyback Raises Questions On Capital Returns And Growth Plans - simplywall.st — simplywall.st positive
Generated 2026-09-26T22:51:58Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertechnology industry clients10-K Item 1A: 'In addition, we generate a significant portion of our revenue from clients in the technology industry.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $25.44, but acceptable to hold if already in. Reason: Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Target $29.94 (+17.7%), stop $24.49 (−3.9%), A.R:R 3.0:1. Score 6.0/10, moderate confidence.
Take-profit target: $29.94 (+17.7% upside). Target $29.94 (+17.7%), stop $24.49 (−3.9%), A.R:R 3.0:1. Stop-loss: $24.49.
Negative momentum.
Progyny, Inc. trades at a P/E of 27.7 (forward 11.0). TrendMatrix value score: 7.7/10. Verdict: Hold.
18 analysts cover PGNY with a consensus score of 4.2/5. Average price target: $34.
What does Progyny, Inc. do?Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits...
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.